Senior Director, Global Value Access and Pricing, NSCLC

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Global Value, Access & Pricing NSCLC Oncology is accountable for defining and driving global value, access, and pricing strategies for Revolution Medicines’ oncology assets. This role serves as the strategic market access leader across the asset lifecycle, ensuring payer, HTA, pricing, reimbursement, and evidence-generation considerations are integrated into development, launch, and commercialization decisions. As the Global Value & Access lead on Disease Area Strategy Teams and governance forums, the Senior Director influences clinical development, indication sequencing, lifecycle management, launch planning, and business development decisions to maximize long-term asset value and sustainable patient access. The role partners closely with Clinical Development, HEOR, Medical Affairs, Regulatory, Commercial, Finance, regional teams, and the European cross-functional organization to align global and regional access strategies. The Senior Director also contributes to building organizational capabilities and may lead and develop team members in support of portfolio priorities. Key responsibilities: Define and drive the global value, access, and pricing strategy for oncology assets across the product lifecycle, ensuring alignment with portfolio objectives, long-term asset value, and sustainable patient access. Influence clinical development, evidence generation, indication sequencing, lifecycle management, and key investment decisions through leadership on Disease Area Strategy Teams and governance forums. Develop differentiated global value propositions and pricing strategies, including launch sequencing, pricing architecture, reference pricing considerations, and net price corridor management across major markets. Anticipate and assess market access risks and opportunities, including competitive dynamics, evolving payer requirements, HTA frameworks, healthcare policy changes, and reimbursement considerations, translating insights into actionable strategic recommendations. Lead global market access and HTA readiness, including EU Joint Clinical Assessment (JCA) strategy, in partnership with European teams to align evidence generation, value strategy, and access objectives. Partner across global and regional functions to ensure market access considerations are integrated into development, launch, commercialization, and lifecycle planning. Serve as a strategic advisor to senior leadership on pricing, reimbursement, launch readiness, lifecycle management, portfolio prioritization, and business development opportunities. Strengthen organizational capability through leadership, mentoring, and the establishment of best practices while representing the Global Value & Access function in cross-functional and external forums as appropriate. Required Skills, Experience and Education: Bachelor’s degree required; advanced degree (PhD, PharmD, MD, MBA, MPH, MSc, or equivalent) preferred. 12+ years of progressive experience in market access, pricing, HEOR, commercial strategy, or related functions within the biopharmaceutical industry, including global leadership responsibilities. Deep expertise in global pricing, reimbursement, market access, and oncology product development, with a strong understanding of payer systems, HTA processes, and evolving reimbursement frameworks across major markets. Demonstrated success influencing clinical development, evidence generation, launch planning, and commercialization strategies to optimize payer and HTA outcomes. Proven ability to shape strategy, influence senior leadership, and drive cross-functional alignment in complex, matrixed organizations. Strong strategic, analytical, and decision-making capabilities, with the ability to translate complex business challenges into actionable recommendations. Demonstrated leadership, communication, and stakeholder management skills, including experience mentoring and developing talent. Preferred Skills: Experience in thoracic oncology, lung cancer, precision oncology, or biomarker-driven therapies. Understanding of companion diagnostic reimbursement and testing access considerations. Familiarity with emerging global healthcare policy and pricing reforms, including U.S. IRA, EU pharmaceutical legislation, and EU JCA. Experience in a clinical-stage, pre-commercial, or rapidly growing biotechnology environment. #LI-JW1 #LI-Remote We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message. Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address. If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.